Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: The basis for an adjuvant therapy trial

Journal of Clinical Oncology

Volumn 15, Issue 4, 1997, Pages 1465-1469

  D'Amico, A V ^a   Whittington, R ^a   Malkowicz, S B ^a   Schultz, D ^a   Tomaszewski, J E ^a   Wein, A ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY;

EID: 0030907162     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.4.1465     Document Type: Article

References (35)

1. Scott WW, Boyd HL: Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: A retrospective study based upon 25 years of experience. J Urol 101:86-92, 1969
2. Soloway MS, Sharifi R, Wajsman Z, et al: Randomized prospective study - Radical prostatectomy preceded by androgen blockade in cT2b prostate cancer - Initial results. J Urol 155:555A, 1996 (abstr 976)
3. Soloway MS, Sharifi R, Wajsman Z, et al: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxMo) prostate cancer. J Urol 154:424-428, 1995
4. Jewett HJ, Bridge RW, Gray GF Jr, et al: The palpable nodule of prostate cancer. Results 15 years after radical excision. JAMA 203:115-118, 1968
5. Zincke H, Oesterling JE, Blute ML, et al: Long term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. Part 2. J Urol 152:1850-1857, 1994
6. Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomic radical retropubic prostatectomy: Results at 10 years. Part 2. J Urol 152:1831-1836, 1994
7. Culp OS: Radical perineal prostatectomy: Its past, present, and possible future. J Urol 98:618-626, 1968
8. Jewett HJ, Eggleston JC, Yawn DH: Radical prostatectomy in the management of carcinoma of the prostate: Probable causes of some therapeutic failures. J Urol 107:1034-1040, 1972
9. Benson RC Jr, Tomera KM, Zincke H, et al: Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for adenocarcinoma confined to the prostate. J Urol 131:1103-1106, 1984
10. Blute ML, Nativ O, Zincke H, et al: Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: Influence of tumor deoxyribonucleic acid ploidy. J Urol 142:1262-1265, 1989
11. Partin AW, Pearson JD, Landis PK, et al: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastasis. Urology 43:649-659, 1994
12. D'Amico AV, Whittington R, Malkowicz SB, et al: An analysis of the time course of postoperative prostate-specific antigen failure in patients with positive surgical margins: Implications on the use of adjuvant therapy. Urology 47:538-547, 1996
13. Myrtle JF, Klimley PG, Ivor LP: Clinical utility of prostate-specific antigen (PSA) in the management of prostate cancer. Adv Cancer Diagn, San Diego, CA, Hybritech, 1986
14. Beahrs OH, Henson DE, Hutter RVP: American Joint Committee on Cancer, Manual for Staging Cancer (ed 4). Philadelphia, PA, Lippincott, 1992
15. Gleason DF, Veterans Administration Cooperative Urological Research Group: Histologic grading and staging of prostatic carcinoma, in Tannenbaum M (ed): Urologic Pathology. Philadelphia, PA, Lea & Febiger, 1977, pp 171-187
16. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-201, 1972
17. Kaplan, EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-475, 1958
18. Labrie F, Cusan L, Gomez J, et al: Down-staging of early stage prostate cancer before radical prostatectomy: Neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist. Urology 44:29-37, 1994
19. Debruyne MJ, Forster, G, Schulman CC, et al: European study of neoadjuvant combined androgen deprivation therapy in T2-3,N0,M0 prostatic carcinoma. J Urol 155:645A, 1996 (abstr 1337)
20. Van Poppel H, Ridder DD, Elgamal AA, et al: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial. J Urol 154:429-434, 1995
21. McNeal JE: Cancer volume and site of origin of adenocarcinoma of the prostate: Relationship to local and distant spread. Hum Pathol 23:258-263, 1992
22. Partin AW, Epstein JI, Cho KR, et al: Morphometric measurement of tumor volume and percent of gland involvement as predictors of pathologic stage in clinical stage B prostate cancer. J Urol 141:341-346, 1989
23. Babaian J, Troncoso P, Steelhammer LC, et al: Tumor volume and prostate specific antigen: Implications for early detection and defining a window of curability. J Urol 154:1808-1812, 1995
24. Ohori M, Goad JR, Wheeler TM, et al: Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 152:1843-1849, 1994
25. Connolly JA, Shinohara K, Presti JC Jr, et al: Local recurrence after radical prostatectomy: Characteristics in size, location, and relationship to prostate-specific antigen and surgical margins. Urology 47:225-231, 1996
26. Sklar GN, Eddy HA, Jacobs SC, et al: Combined antitumor effect of suramin plus irradiation in human prostate cancer cells: The role of apoptosis. J Urol 150:1526-1532, 1993
27. Veldscholte J, Berrevoets C, Mulder E: Studies on the human prostatic cancer cell line LNCaP. J Steriod Biochem Mol Biol 49:341-346, 1994
28. Schild SE, Buskirk SJ, Wong WW, et al: The use of radiotherapy for patients with isolated elevation of serum prostate specific antigen following radical prostatectomy. J Urol 156:1725-1729, 1996
29. Lange PH, Lightner DJ, Medini E, et al: The effect of radiation therapy after radical prostatectomy in patients with elevated prostate specific antigen levels. J Urol 144:927-931, 1990
30. Hudson MA, Catalona WJ: Effect of adjuvant radiation therapy on prostate specific antigen following radical prostatectomy. J Urol 143:1174-1178, 1990
31. Kaplan ID, Bagshaw MA: Serum prostate specific antigen after post-prostatectomy radiotherapy. Urology 39:401-407, 1992
32. Morris MM, Dallow KC, Zietman AL, et al: Adjuvant and salvage irradiation following radical prostatectomy for prostate cancer. Int J Radiat Oncol Biol Phys 32:144, 1995 (suppl 1, abstr)
33. Wu JJ, King SC, Montana GS, et al: The efficacy of postprostatectomy radiotherapy in patients with an isolated elevation of serum prostate specific-antigen. Int J Radiat Oncol Biol Phys 32:317-321, 1995
34. McCarthy JF, Catalona WJ, Hudson MA: Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: Early versus delayed treatment. J Urol 151:1575-1578, 1994
35. Hanks GE, Hanlon AL, Hudes G, et al: Patterns of failure analysis of patients with high pretreatment prostate-specific antigen levels treated by radiation therapy: The need for improved systemic and locoregional treatment. J Clin Oncol 14:1093-1097, 1996